Methanol / Ethylene Glycol

Drug Overview

In the high-stakes, intensive care environment of Nephrology and medical toxicology, the ingestion of toxic alcohols represents a profound, time-sensitive medical emergency. The Methanol / Ethylene Glycol drug class requires immediate, life-saving intervention to halt systemic poisoning. The definitive standard of care for severe ingestions is the synergistic application of Fomepizole + Hemodialysis.

This combined approach functions as a highly precise, dual-action Targeted Therapy. Fomepizole acts as a molecular “brake,” halting the enzymatic conversion of parent alcohols into their lethal metabolites. Concurrently, Hemodialysis acts as an extracorporeal physical clearance system. Together, they prevent the massive precipitation of calcium oxalate crystals—which effectively “freezes” and destroys the renal tubules—and rapidly reverse the profound, life-threatening metabolic acidosis that leads to cardiovascular collapse and brain death.

• Generic Name: Fomepizole (often combined with intermittent Hemodialysis)
• US Brand Names: Fomepizole: Antizol
• Route of Administration: Intravenous (IV) infusion (Fomepizole) and Extracorporeal Blood Circuit (Hemodialysis).
• FDA Approval Status: Fomepizole is fully FDA-approved as an antidote for documented or suspected ethylene glycol or methanol toxicity, either alone or in combination with hemodialysis. Hemodialysis is the universally recognized, standard-of-care intervention mandated by global EXTRIP (Extracorporeal Treatments in Poisoning) guidelines for severe toxic alcohol poisonings.
  
  Learn about Fomepizole and Hemodialysis for Methanol and Ethylene Glycol toxicity. Emergency dialysis prevents permanent acidosis. Read our safety guide. Methanol / Ethylene Glycol

What Is It and How Does It Work? (Mechanism of Action)

Ethylene glycol (found in antifreeze) and methanol (found in windshield washer fluid and bootleg liquor) are relatively non-toxic in their parent forms. The lethal damage occurs when the liver enzyme alcohol dehydrogenase (ADH) metabolizes them into toxic acids. Ethylene glycol is converted into glycolic and oxalic acid. Methanol is converted into formic acid.

At the molecular and physiological level, this combination therapy intercepts the pathology via two distinct mechanisms:

1. Fomepizole (Enzyme Blockade): Fomepizole is a potent, competitive inhibitor of alcohol dehydrogenase. It binds directly to the active site of the ADH enzyme with an affinity 8,000 times greater than ethanol. By occupying this receptor site, it completely stalls the metabolic cascade. The parent toxic alcohols remain unmetabolized in the bloodstream, preventing the formation of oxalic acid (which destroys the kidneys) and formic acid (which causes blindness and systemic acidosis).
2. Hemodialysis (Extracorporeal Clearance and pH Correction): While Fomepizole stops the creation of new toxins, Hemodialysis physically removes both the parent alcohols and the already formed toxic acids from the patient’s blood. The patient’s blood is pumped through a semipermeable dialyzer membrane. The small, water-soluble molecules of ethylene glycol, methanol, and their toxic metabolites diffuse across the membrane and are flushed away. Simultaneously, the dialysis machine pumps high concentrations of bicarbonate directly into the patient’s bloodstream, instantly correcting the lethal metabolic acidosis.

By blocking the formation of oxalic acid, this Targeted Therapy prevents the formation of insoluble calcium oxalate crystals, thereby preventing the kidneys from “freezing” into a state of irreversible acute tubular necrosis.

FDA-Approved Clinical Indications

Primary Indication

• Emergency dialysis to prevent the freezing of kidneys and permanent acidosis: Indicated for severe ethylene glycol or methanol poisoning characterized by high anion gap metabolic acidosis, acute kidney injury, visual disturbances, or dangerously high serum toxic alcohol concentrations.

Other Approved Uses

• General Medical / Toxicology: Suspected toxic alcohol ingestion presenting with an unexplained osmolar gap and metabolic acidosis, even before definitive serum toxic alcohol levels result from the laboratory.
• Nephrology: Management of severe, refractory metabolic acidosis secondary to toxic ingestions unresponsive to standard intravenous bicarbonate therapy.

Dosage and Administration Protocols

Dosing for Fomepizole requires meticulous adjustment when combined with Hemodialysis. Because Fomepizole is a small molecule, it is rapidly removed by the dialysis machine itself, necessitating highly frequent re-dosing during the extracorporeal treatment to maintain enzymatic blockade.

Dose Adjustments for Renal/Hepatic Insufficiency and Special Populations

• Renal Impairment: Because the primary indication usually involves acute renal failure, Fomepizole dosing during continuous or intermittent renal replacement therapy is heavily protocoled to match the clearance rate of the specific dialyzer filter used.
• Hepatic Impairment: Fomepizole is metabolized by the liver. While specific adjustments for pre-existing hepatic disease are not strictly defined due to the emergent nature of the condition, prolonged action and altered metabolism should be anticipated in severe cirrhosis.

Clinical Efficacy and Research Results

Current critical care and nephrology guidelines (2020-2026), including those established by the EXTRIP workgroup, establish Fomepizole and Hemodialysis as the absolute gold standard for toxic alcohol ingestion.

• Prevention of End-Stage Renal Disease (ESRD): When Fomepizole and Hemodialysis are initiated early (before serum creatinine rapidly rises), the incidence of irreversible kidney failure requiring lifelong dialysis drops to less than 5%. The therapy effectively prevents the catastrophic precipitation of calcium oxalate.
• Acid-Base Normalization: The initiation of Hemodialysis resolves profound metabolic acidosis (e.g., raising arterial pH from a lethal 6.9 to a stable 7.35) often within the first 2 to 4 hours of treatment, rescuing cardiovascular hemodynamics.
• Survival Rates: Prompt application of this dual therapy yields survival rates exceeding 90% to 95% in patients who arrive at the emergency department prior to the onset of severe anoxic brain injury or comatose respiratory failure.

Safety Profile and Side Effects

(Note: There is no Black Box Warning for Fomepizole; however, the overall clinical scenario of toxic alcohol poisoning carries an inherently high risk of mortality).

Common Side Effects (>10%)

• Neurological (Fomepizole): Headache, dizziness, and mild lethargy.
• Gastrointestinal (Fomepizole): Nausea, vomiting, and unpleasant metallic taste.
• Hemodynamics (Hemodialysis): Hypotension (low blood pressure) is very common during dialysis, as fluids and toxins are rapidly pulled from the vascular space. (Management: Careful adjustment of ultrafiltration rates and intravenous fluid boluses).

Serious Adverse Events

• Hypocalcemia: Ethylene glycol metabolism consumes massive amounts of systemic calcium to form calcium oxalate. This can lead to life-threatening hypocalcemia, causing seizures and cardiac arrhythmias. (Management: Continuous cardiac monitoring and aggressive intravenous calcium gluconate replacement during dialysis).
• Bleeding Complications: Hemodialysis circuits require anticoagulation (typically Heparin) to prevent blood from clotting in the machine. This exposes the patient to a risk of severe bleeding. (Management: Regional citrate anticoagulation or heparin-free dialysis protocols can be utilized in high-risk patients).
• Anaphylaxis (Fomepizole): Rare but severe allergic reactions to the medication. (Management: Immediate cessation of the infusion, epinephrine, and airway support).

Research Areas

In the realm of regenerative medicine, acute tubular necrosis (ATN) induced by toxic calcium oxalate precipitation is a prime model for studying renal repair mechanisms. When the kidneys are functionally “frozen” by toxic alcohols, the epithelial cells lining the proximal tubules undergo rapid necrosis. Current research evaluates the introduction of Mesenchymal Stem Cells (MSCs) following the stabilization of the patient via Fomepizole and Hemodialysis. Because Hemodialysis rapidly clears the toxic environment, it leaves behind a clean, albeit damaged, cellular matrix. Experimental models suggest that infusing MSCs post-dialysis can accelerate the regeneration of the tubular epithelium, promoting faster recovery from dialysis-dependent acute kidney injury and preventing the long-term fibrotic scarring that leads to Chronic Kidney Disease.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Arterial Blood Gas (ABG): To immediately quantify the severity of the metabolic acidosis (blood pH, bicarbonate levels).
• Comprehensive Metabolic Panel (CMP): To calculate the Anion Gap and check baseline renal function (BUN, Creatinine), as well as to tightly monitor serum calcium levels.
• Serum Osmolality: To calculate the Osmolar Gap, which is a rapid, indirect surrogate marker for the presence of unmeasured toxic alcohols before specific drug levels return from the lab.
• Toxicology Screen: Specific serum levels for ethylene glycol, methanol, acetaminophen, and salicylates.

Precautions During Treatment

• Airway Management: Profound acidosis drives severe hyperventilation (Kussmaul respirations) and depresses the central nervous system. Patients frequently require elective endotracheal intubation to protect their airway before initiating the dialysis catheter insertion.
• Vascular Access Vigilance: A large-bore central venous catheter (dialysis line) must be placed emergently. Strict sterile technique is required to prevent life-threatening central line-associated bloodstream infections (CLABSI).

Do’s and Don’ts

• DO initiate a Fomepizole infusion immediately based strictly on clinical suspicion, severe acidosis, and an elevated osmolar gap; do not wait hours for the confirmatory toxic alcohol blood levels to return from the lab.
• DO continuously monitor the patient’s heart rhythm, as rapid shifts in potassium, calcium, and acid-base status during dialysis can trigger sudden arrhythmias.
• DO check the patient’s blood glucose frequently, as both toxic alcohol metabolism and the dialysis procedure can cause severe hypoglycemia.
• DON’T pause the Fomepizole infusion while the dialysis machine is running. The drug must be continually replaced to keep the toxic enzymes blocked.
• DON’T assume that a normal blood pH upon arrival means the patient is safe; if the toxic alcohol was ingested recently, the enzymes may not have converted it into acid yet. Fomepizole must be given to prevent this impending drop.

Legal Disclaimer

The content provided in this guide is for informational and educational purposes only and is not intended to serve as a substitute for professional medical advice, diagnosis, or treatment. Toxic alcohol ingestion is a profound medical emergency requiring immediate, intensive care unit-level intervention. Always seek the advice of your physician, toxicologist, nephrologist, or other qualified healthcare provider with any questions you may have regarding emergency medical conditions, dialysis protocols, or poison control management. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.